UEG Week 2022

Is IL-23 the super target?

What is the best dose of adalimumab in CD?

What is new in anti-TNFα therapy?

Treat-to-target with ustekinumab - why didn't it work?

The benefit of early intervention in CD

Treat-to-target still alive?

Personalized therapy - de-escalation strategies

TYK2 Deucravacitinib in ulcerative colitis

Combination therapy: week 38 efficacy and safety data from the VEGA study

Postoperative monitoring matters!

Longterm potential benefit of a combIo therapy

Anti-IL-23 monoclonal antibodies: is it better to target IL-23 only than IL-23 and IL-12?

Once more a shocking message: be aware of steroids!

VEGA - the story continues

No matter what you use - treat early!

Enhanced treatment algorithm for the management of CD

Treat-to-target strategy is superior to conventional step-care in active patients to gain remission

T reg - a new therapeutic target in IBD?

Treating the patient as a whole

Pharmacokinetics of ustekinumab in the STARDUST trial

Small molecules in crohn's disease

Oral anti-integrin therapy in IBD - new data, new chances?

You can still treat severe biofailure in CD

Explosion of new drugs

Thinking out of the box - co-medication of the elderly

VEGA - l'histoire continue

Treating the patient as a whole

Small molecules nel morbo di crohn

Ανεξάρτητα του τι θα χορηγήσεις χορήγησέ το έγκαιρα!

Les résultats à long terme d'une combIothérapie

Terapia di combinazione: efficacia e sicurezza a 38 settimane nello studio VEGA

Anticorps anti-IL-23: est-il préferabble de cibler l'IL-23 seule plutôt que l'IL-12 et l'IL-23?

Was tun nach der Operation?

Una strategia “Treat-to-target” è superiore rispetto and un approccio convenzionale nel raggiungimento della remissione in pazienti con malattia attiva

Doustna terapia antyintegrynowa - nowe dane, nowe nadzieje?

T reg - nowy cel terapeutyczny w IBD?

Thinking out of the box - Einfluss der Begleitmedikation bei älteren Patienten

Explosión de nuevos fármacos

Μπορείς ακόμη να θεραπεύσεις ανθεκτική στα βιολογικά νόσο του Crohn

Ακόμα ένα πολύ ανησυχητικό μήνυμα: Πρόσεχε τα κορτικοστεροιδή!

TYK2 Deucravacitinib bei Colitis ulcerosa

Update on JAK inhibition in UC

1st JAK inhibitor in CD - a game changer?

S1P receptor modulators

Update on IL-23 inhibition in UC

Histological response and remission induced by mirikizumab

The 1st JAKi in CD

Risankizumab in refractory CD patients

Ozanimod works in young and old UC patient

Upadacitinib - induction therapy in CD

The era of small molecules

Final efficacy and safety results from Upadacitinib 52 weeks maintenance trial in UC patients

JAK-inhibition

Upadacitinib maintenance therapy - final results from U-ACHIEVE

VEGA & LUCENT studies

Estrasimod in moderate to severe active UC

Persistance on therapy and real-world clinical effectiveness of Tofacitinib in ulcerative colitis: data from the ENEIDA registry

Selective IL-23 blockade

Risultati finali di efficacia e sicurezza a 52 settimane di Upadacitinib in colite ulcerosa

Persistenza in terapia ed efficaci clinica di Tofacitinib in colite ulcerosa: dati dal registro ENEIDA

The area of small molecules

JAK-Inhibition

Selective IL-23 Blockade

VEGA & LUCENT studi clinici

Upadacitinib - Induktionsdaten bei CD

Risankizumab dans la maladie de Crohn réfractaire

Treating the elderly - closer surveillance and the importance of co-medication

Updated safety data on JAK inhibitors

Urgency - putting the focus on an important endpoint!

Steroid effects as treatment goals: quality of life and steroid free remission

New endpoints in IBD

Urgency matters!

Patient reported outcomes in IBD

Filgotinib is efficacious in inducing and maintaining histological remission in UC

Patienten gerichtete Endpunkte bei CED

Neue Studienendpunkte in IBD

Explosion of Spanish contributions

Whats's the origin of Crohn's genetics ? The history of IL-23 receptor genetics in Europe

Wo kommt die Crohn-Genetik her? Die Historie der IL-23 Rezeptorgenetik in Europa

Explosión de las comunicaciones españolas

Personalised therapy in IBD

Individualisierte Therapie bei CED